The True Hero of the AI Revolution: Why I Am Investing in Pharmaceuticals

From this point forward, I am investing in pharmaceutical companies. The reason is simple: I believe the pharmaceutical sector is the field that will capture the most direct, revolutionary benefits of the AI "revolution."

When people discuss the primary beneficiaries of the AI era, they almost always point to the power grid or the semiconductor sector. They are not wrong. However, while these infrastructure sectors directly benefit from the expansion of AI, they are not the ones experiencing an actual AI revolution.

In other words, as AI advances, the demand for power and chips will naturally scale up, but the fundamental nature of the power grid or semiconductor manufacturing itself does not undergo a radical transformation.Investing merely in the superficial beneficiaries of a trend is rarely how you generate substantial returns. (While the semiconductor sector has already witnessed an explosive surge, I expect its future growth to transition into a gradual, incremental rise rather than another vertical spike.)

From the Nobel Prize to the Yonsei Forum: Formulating the Thesis 

This conviction is not a product of mere speculation. I formed this investment thesis by connecting two pivotal events: the 2024 Nobel Prize in Chemistry and the 2026 Yonsei-Nobel Forum.

The 2024 Nobel Prize in Chemistry was awarded to David Baker, Demis Hassabis, and John Jumper. They received this ultimate recognition for solving the "protein folding problem," a biological riddle that had eluded humanity for decades. What made their win particularly controversial at the time, however, was that they were computer scientists and AI researchers, rather than traditional laboratory chemists. They didn't solve the problem through manual, physical experimentation; they cracked it using artificial intelligence. Watching this unfold, it became glaringly obvious to me that AI was poised to trigger an unprecedented revolution in the pharmaceutical sector.

Yet, because AI capability in medicine was still developing back then, I held off on investing immediately. The turning point came this year at the 2026 Yonsei-Nobel Forum. I had the privilege of sitting in the audience and listening to David Baker lecture in person. Witnessing the sheer magnitude of AI's current impact on the life sciences solidified my conviction. Right then and there, I resolved to actively allocate my capital into pharmaceutical stocks.

How AI Eradicates the Core Friction of Biotech 

The primary bottlenecks that have historically amplified the costs and suppressed the growth of pharmaceutical companies are the astronomical expenses of clinical trials and the devastating financial penalties of failure. AI elegantly eliminates both.

An AI system can run simulations 24 hours a day, 365 days a year, entirely unconstrained by physical limits. Because candidates are now architected and pre-screened by artificial intelligence, the eventual clinical success rates are incomparable to the traditional era. Furthermore—if I correctly understood the breakthrough presented at the Yonsei-Nobel Forum—we have now reached a stage where AI is actively creating entirely new proteins from scratch. The AI revolution in pharmaceuticals has officially transitioned from a distant possibility into an irreversible reality.

Learning from the Internet Era: Winners vs. Enablers

If you still find yourself skeptical, I invite you to look back at history. When the Internet was first invented and commercialized, the corporations that generated the most wealth were not the telecoms that laid down the physical network lines, nor were they the companies that created the internet infrastructure itself.

The absolute winners of the Internet era were the companies that used the internet to do what was previously impossible. The ultimate crowns did not go to Dell, IBM, or AT&T; they went to Apple, Facebook, Amazon, and Google.

The exact same playbook is playing out in the AI era. Right now, the market is hyper-focused on the companies creating the AI models or building out the heavy AI infrastructure. Granted, those are excellent businesses, and their stock prices will certainly continue to perform well. However, I choose to look past the enablers. I am investing in the companies that harness AI to achieve things that human beings could simply never accomplish before.

No industry fits this description more perfectly than pharmaceuticals. That is why I have initiated my positions in this sector, and why I will continue to build them for the long haul.

Comments

Post a Comment

Popular posts from this blog

[Investment Philosophy #1] Never Miss the Chance to Buy Great Stocks at a Discount

The core of my first investment principle is simple:  When a fundamentally strong company experiences a sharp decline due to external factors, buy aggressively.  In other words, no matter how excellent a company is, never pay an excessive premium. Many investors emphasize the importance of holding high-quality stocks for the long term. I agree. However, the more critical question is  when  to buy those stocks. While great companies tend to rise over time, simply buying at any price rarely leads to significant outperformance. More importantly, buying at a peak forces you to endure unnecessary losses and wait a long time just to break even. This is why it is crucial to act when good stocks experience a major correction. But why do most people hesitate to buy during such downturns? I believe there are two primary reasons. 1. Lack of Conviction  The fear that a stock will continue to fall indefinitely often stems from a lack of confidence in one’s own research. If y...
Read more

The Importance of Social Science in Investing

Many people study investing by reading books on trading techniques, financial statements, or macroeconomics. Some dive deeper into specialized fields like semiconductors. But does mastering these subjects alone lead to investment success? My answer is a firm "No." While I don't discount the importance of technical and financial knowledge, I believe there is another essential pillar that is often overlooked: the social sciences, philosophy, history, and literature. To be clear, it's not that financial books are unnecessary; rather, I believe that studying the humanities is a prerequisite for any serious investor. The Root of Every Stock is Society In this post, I want to discuss the importance of social science in investing. Why is it so critical? The answer lies in the term itself. Social science teaches us about society, and nothing in this world exists in isolation from it. This applies directly to the stock market. At the root of every stock is a company, and ever...
Read more

The Importance of History in Investing

In my previous post, I discussed the importance of social sciences in stock investing. This time, I want to talk about why history is just as crucial. First, why does history matter in the context of the stock market? (In fact, history is essential not just for investing, but for life itself.) I believe the answer can be found in E.H. Carr’s What is History? . Based on his insights, I’d like to highlight two main reasons why history is vital for investors. 1. History Repeats Itself E.H. Carr argued that while the past doesn’t repeat itself "exactly," there are common laws and patterns shared between historical events. Because of these patterns, history tends to rhyme. If we understand this, we can predict the future to a certain extent by looking at what has already happened. 2. Breaking the Cycle of Mistakes Time flows forward and new events emerge every day, so why does history keep repeating? This is where I’ve added my own perspective: History repeats itself because most...
Read more